Skip to content

Study · Not a test of the peptide alone · 2026

8 results

Short-term comparative effects of semaglutide, either alone or in conjunction with canagliflozin, on early diabetic kidney disease.

Long W, Ningning L, Weijun H

Pakistan journal of pharmaceutical sciences1 Jul 2026

PMID42170981 (opens in a new tab)DOI10.36721/pjps.2026.39.7.204.1 (opens in a new tab)PepBankPUB-42170981
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone8

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

  1. 01HumanNot a test of Semaglutide aloneRandomized controlled trialEfficacy outcome

    In adults with early diabetic kidney disease, canagliflozin plus semaglutide reduced UACR more than monotherapy and placebo at 24 weeks.

    In plain wordsIn people with early diabetic kidney disease, canagliflozin and semaglutide together lowered urine albumin more than either drug alone or placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseUACR reduction at 24 weeks
    Study

    n = 120

    Comparator
    Monotherapy and placebo
    Analysis
    Primary
    Outcome group
    Kidney function · Kidney and urinary

    Source sentences

    Summary
    At 24 weeks, combination therapy achieved significantly greater reductions in UACR compared with monotherapy and placebo (P < 0.05).
    2 context sentences
    Summary · context
    In this randomized controlled trial, 120 patients with early-stage diabetic kidney disease were randomly allocated (1:1:1:1) to four groups (n = 30 each): canagliflozin (100 mg orally once daily), semaglutide (0.25 mg once weekly with escalation to 1.0 mg after 4 weeks), combination treatment, or placebo/control.
    Summary · context
    All participants were provided standard background care.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  2. 02HumanNot a test of Semaglutide aloneRandomized controlled trialEfficacy outcome

    In adults with early diabetic kidney disease, a small reduction in eGFR occurred across treatment groups without significant between-group differences.

    In plain wordsIn people with early diabetic kidney disease, kidney filtering fell slightly in all groups, with no significant difference between groups.

    Peptide
    Semaglutide
    Outcome
    No significant changeeGFR change
    Study

    n = 120

    Comparator
    Between treatment groups
    Analysis
    Primary
    Outcome group
    Kidney function · Kidney and urinary

    Source sentences

    Summary
    Across treatment groups, a small reduction in eGFR was observed without significant between-group differences.
    2 context sentences
    Summary · context
    In this randomized controlled trial, 120 patients with early-stage diabetic kidney disease were randomly allocated (1:1:1:1) to four groups (n = 30 each): canagliflozin (100 mg orally once daily), semaglutide (0.25 mg once weekly with escalation to 1.0 mg after 4 weeks), combination treatment, or placebo/control.
    Summary · context
    All participants were provided standard background care.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  3. 03HumanNot a test of Semaglutide aloneRandomized controlled trialEfficacy outcome

    In adults with early diabetic kidney disease, the canagliflozin plus semaglutide combination showed better HbA1c results than single-agent therapy.

    In plain wordsIn people with early diabetic kidney disease, canagliflozin and semaglutide together gave better HbA1c results than either drug alone.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedHbA1c
    Study

    n = 120

    Comparator
    Single-agent therapy
    Analysis
    Secondary
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Measurements of HbA1c, fasting glucose, HOMA-IR, lipid parameters, and inflammatory markers showed better results in the combination therapy group compared to single-agent therapy (P < 0.05).
    2 context sentences
    Summary · context
    In this randomized controlled trial, 120 patients with early-stage diabetic kidney disease were randomly allocated (1:1:1:1) to four groups (n = 30 each): canagliflozin (100 mg orally once daily), semaglutide (0.25 mg once weekly with escalation to 1.0 mg after 4 weeks), combination treatment, or placebo/control.
    Summary · context
    All participants were provided standard background care.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  4. 04HumanNot a test of Semaglutide aloneRandomized controlled trialEfficacy outcome

    In adults with early diabetic kidney disease, the canagliflozin plus semaglutide combination showed better fasting glucose results than single-agent therapy.

    In plain wordsIn people with early diabetic kidney disease, canagliflozin and semaglutide together gave better fasting glucose results than either drug alone.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedFasting glucose
    Study

    n = 120

    Comparator
    Single-agent therapy
    Analysis
    Secondary
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Measurements of HbA1c, fasting glucose, HOMA-IR, lipid parameters, and inflammatory markers showed better results in the combination therapy group compared to single-agent therapy (P < 0.05).
    2 context sentences
    Summary · context
    In this randomized controlled trial, 120 patients with early-stage diabetic kidney disease were randomly allocated (1:1:1:1) to four groups (n = 30 each): canagliflozin (100 mg orally once daily), semaglutide (0.25 mg once weekly with escalation to 1.0 mg after 4 weeks), combination treatment, or placebo/control.
    Summary · context
    All participants were provided standard background care.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  5. 05HumanNot a test of Semaglutide aloneRandomized controlled trialEfficacy outcome

    In adults with early diabetic kidney disease, the canagliflozin plus semaglutide combination showed better HOMA-IR results than single-agent therapy.

    In plain wordsIn people with early diabetic kidney disease, canagliflozin and semaglutide together gave better insulin resistance results than either drug alone.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedHOMA-IR
    Study

    n = 120

    Comparator
    Single-agent therapy
    Analysis
    Secondary
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Measurements of HbA1c, fasting glucose, HOMA-IR, lipid parameters, and inflammatory markers showed better results in the combination therapy group compared to single-agent therapy (P < 0.05).
    2 context sentences
    Summary · context
    In this randomized controlled trial, 120 patients with early-stage diabetic kidney disease were randomly allocated (1:1:1:1) to four groups (n = 30 each): canagliflozin (100 mg orally once daily), semaglutide (0.25 mg once weekly with escalation to 1.0 mg after 4 weeks), combination treatment, or placebo/control.
    Summary · context
    All participants were provided standard background care.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  6. 06HumanNot a test of Semaglutide aloneRandomized controlled trialEfficacy outcome

    In adults with early diabetic kidney disease, the canagliflozin plus semaglutide combination showed better lipid parameters than single-agent therapy.

    In plain wordsIn people with early diabetic kidney disease, canagliflozin and semaglutide together gave better blood fat results than either drug alone.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedLipid parameters
    Study

    n = 120

    Comparator
    Single-agent therapy
    Analysis
    Secondary
    Outcome group
    Lipids · Metabolic and weight

    Source sentences

    Summary
    Measurements of HbA1c, fasting glucose, HOMA-IR, lipid parameters, and inflammatory markers showed better results in the combination therapy group compared to single-agent therapy (P < 0.05).
    2 context sentences
    Summary · context
    In this randomized controlled trial, 120 patients with early-stage diabetic kidney disease were randomly allocated (1:1:1:1) to four groups (n = 30 each): canagliflozin (100 mg orally once daily), semaglutide (0.25 mg once weekly with escalation to 1.0 mg after 4 weeks), combination treatment, or placebo/control.
    Summary · context
    All participants were provided standard background care.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  7. 07HumanNot a test of Semaglutide aloneRandomized controlled trialEfficacy outcome

    In adults with early diabetic kidney disease, the canagliflozin plus semaglutide combination showed better inflammatory marker results than single-agent therapy.

    In plain wordsIn people with early diabetic kidney disease, canagliflozin and semaglutide together gave better inflammation marker results than either drug alone.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedInflammatory markers
    Study

    n = 120

    Comparator
    Single-agent therapy
    Analysis
    Secondary
    Outcome group
    Inflammation markers · Immune and inflammation

    Source sentences

    Summary
    Measurements of HbA1c, fasting glucose, HOMA-IR, lipid parameters, and inflammatory markers showed better results in the combination therapy group compared to single-agent therapy (P < 0.05).
    2 context sentences
    Summary · context
    In this randomized controlled trial, 120 patients with early-stage diabetic kidney disease were randomly allocated (1:1:1:1) to four groups (n = 30 each): canagliflozin (100 mg orally once daily), semaglutide (0.25 mg once weekly with escalation to 1.0 mg after 4 weeks), combination treatment, or placebo/control.
    Summary · context
    All participants were provided standard background care.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  8. 08HumanNot a test of Semaglutide aloneRandomized controlled trialSafety outcome

    In adults with early diabetic kidney disease, rates of adverse events were similar between the treatment groups.

    In plain wordsIn people with early diabetic kidney disease, side effect rates were similar across the treatment groups.

    Peptide
    Semaglutide
    Outcome
    No significant changeAdverse event rates
    Study

    n = 120

    Comparator
    Between treatment groups
    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    Rates of adverse events were similar between the groups.
    2 context sentences
    Summary · context
    In this randomized controlled trial, 120 patients with early-stage diabetic kidney disease were randomly allocated (1:1:1:1) to four groups (n = 30 each): canagliflozin (100 mg orally once daily), semaglutide (0.25 mg once weekly with escalation to 1.0 mg after 4 weeks), combination treatment, or placebo/control.
    Summary · context
    All participants were provided standard background care.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.